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This Research Topic assembles for the first time a comprehensive
selection of articles (mini review, review articles, original research,
and opinion articles) on the bioluminescence resonance energy
transfer (BRET) technology. BRET is a natural phenomenon
known in several marine organisms. It relies on the non-radiative
transfer of energy from an appropriate energy donor to an energy
acceptor, provided that both are located at a distance lower than
10 nm [see Ref. (1) for a basic and theoretical introduction]. BRET
has been first applied to the detection of protein–protein interac-
tions (PPIs) in 1999 (2). Since then, the technology constantly
evolved by combining new donor and acceptor couples and devel-
oping various BRET assay formats as discussed in the Mini Review
article of De et al. (3).
Many BRET assays have been developed to study the oligomer-
ization of seven-transmembrane-spanning G protein-coupled
receptors (GPCRs). The BRET technology provides an attrac-
tive way to study this phenomenon in intact cells without the
need of solubilization of receptors from their natural membrane
environment. The overwhelming majority of BRET-based studies
conclude that GPCRs do indeed exist as dimers or higher-order
oligomers when transfected into cells at physiological levels. Three
of the articles of this Research Topic discuss BRET assays that have
been developed to properly address the specificity of BRET sig-
nals obtained upon expression of different GPCRs (1, 4, 5). The
current consensus confirms that several different BRET assays are
needed to evaluate the specificity of BRET signals. The precise role
of each of these assays remains a source of controversy in the field
(4). Further refinement of BRET control experiments and appli-
cation of new techniques like single-molecule measurements and
functional in vivo studies are likely to provide new insights to the
existence and physiological relevance of GPCR oligomerization.
Not surprisingly, GPCR oligomerization is the main issue of four
articles of this Research Topic (4–7) ranging from studies on class
A and B GPCR homo- and heteromers using BRET or alternative
approaches like time-resolved FRET measurements.
Apart from performing the proper control experiments,
another important issue in the BRET field concerns the proper
interpretation of stimulus-induced BRET signals. In the context of
GPCR oligomerization, agonist-induced BRET signals can be gen-
erated by an agonist-driven oligomerization or agonist-induced
conformational changes within preassembled oligomers. Discrim-
ination between these two possibilities is not trivial but has become
possible due to the development of BRET donor saturation exper-
iments in the absence and presence of receptor stimulation (8, 9).
This issue, to which BRET has made a significant contribution,
is obviously of general importance for the field of PPIs. This is
illustrated by the articles describing the interaction of the protease-
activated receptor 1 and 2 with its cognate G proteins as described
by Ayoub and Pin (10) and Ayoub et al. (11).
The BRET technology has been extended toward other recep-
tor families like tyrosine kinase receptors and cytokine receptors.
This diversification demonstrates the general feature of this tech-
nique. These studies did not only address the question of receptor
oligomerization but also monitored the real-time interaction of
receptors with various effector molecules such as Grb2, PTP1-B,
PLC-γ1, etc. This important aspect is discussed in the review arti-
cle of Siddiqui et al. (12). Receptor–effector interactions have been
also monitored by BRET for two privileged GPCR interacting part-
ners, heterotrimeric G proteins and β-arrestins, as documented in
articles of this Research Topic (6, 10, 11, 13).
A more recent application of BRET concerns the development
of biosensors to monitor downstream events of cellular signal-
ing like the generation of second messengers and activation of
intracellular kinases. These sensors are typically composed of the
energy donor and acceptor separated by an assay-specific domain
that changes its conformation upon second messenger binding or
phosphorylation, thus modifying the position of the donor and
acceptor and consequently the BRET signal. Similar sensors have
been developed for FRET applications, which served as source of
inspiration for the development of the BRET sensors. The articles
from Salahpour et al. (13) and Xu et al. (2) describe the design and
validation of cAMP and ERK sensors.
The high reproducibility of BRET and the robustness of the
measurements make BRET an interesting option for the design of
high throughput screening assays. Two applications are discussed
in this Research Topic. The first concerns the design of an assay for
the identification of compounds that specifically activate GPCR
heteromers (6) based on the recruitment of β-arrestin to GPCR
heteromers. The second case concerns the identification of PPI
inhibitors (14).
Taken together, this Research Topic provides an illustrative
overview of the principles and applications of the BRET tech-
nology that should be of interest for any scientist interested in
monitoring PPI in intact cells.
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